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ABSTRACT 
WESTIN T: ORNITHINE DECARBOXYLASE IN MALIGNANT TUMOURS. 
Departments of Otolaryngology and Surgery, University of Göteborg, Sahlgrenska hospital, 
S-413 45 Göteborg, SWEDEN. 
Ornithine decarboxylase (ODC) is a rate-limiting enzyme for the synthesis of polyamines. 
Polyamines regulate DNA synthesis by a mechanism which is not fully understood. High 
levels of polyamines and ODC activity are associated with rapid cell growth, particularly in tu­
mour tissues. The aim of this study was to evaluate ODC activity as a possible marker for 
rapid alterations in tumour growth and to determine whether this method could be used to 
establish whether nutritional support in cancer patients can stimulate tumour cell proliferation. 
Weight-loosing head and neck cancer patients and tumour-bearing mice (MCG 101 C57/BL) 
were studied during different feeding regimens. The ODC activity in tumour tissue was inves­
tigated in re lation to 1. histopathological differentiation, 2. DNA content, 3. thymidine and 
bromodeoxyuridine (BrdUrd) incorporation into DNA and 4. Ki-67 reactivity. The energy state 
of tumour tissue was determined in vivo with Nuclear Magnetic Resonance-spectroscopy (31P-
NMR) and in vitro with high performance liquid chromatography (HPLC). 
After 24 hours of starvation, a significant reduction of tumour growth was demonstrated in 
the experimental tumour, along with a reduction of ODC activity, an accumulation of cells in 
the GoGl phase and a reduction of cells incorporating thymidine or BrdUrd into DNA. The en­
ergy charge of the tumour tissue was reduced compared to freely fed animals. Refeeding after 24 
hours of starvation restored the energy charge of tumour tissue to pre-starvation levels and there 
was a general response of all variables but with different lag phases. ODC activity responded 
rapidly and reached higher than pre-starvation values within 1 h. The magnitude of this response 
to refeeding was related to the carbohydrate content of the food and to the levels of plasma in­
sulin. 
After specific inhibition of ODC with difluoromethylornithine (DFMO) a prolonged poten­
tial doubling time of the tumour was demonstrated. There was a prolonged DNA-synthesis 
time, causing an accumulation of cells in the G2M phase and an increased fractional cell loss. 
The energy charge of tumour tissue was not reduced. 
Tumour biopsies from head and neck cancer patients demonstrated aneuploidy in 70% of the 
patients and a growth fraction of around 55% of tumour cells. High ODC activity in tumour 
tissue was demonstrated mainly among poorly differentiated tumours and ODC activity was cor­
related to the proportion of aneuploidic cells in the tumour. High ODC activity may indicate a 
poor short term-survival (one year). 
"Enteral nutrition" to cachectic cancer patients increased the proportion of aneuploidic cells 
in tumours compared to spontaneous feeding. "Parenteral nutrition" did not produce any cytoki-
netic effects in the tumour. 
It was concluded that experimental tumour growth is highly dependent on the host feeding. 
However, there was little evidence to support the fear that nutritional support in cancer patients 
stimulates tumour cell proliferation. ODC is suggested to have a direct role in the induction and 
promotion of cell division. Determination of ODC activity may have prognostic significance 
for survival and can probably be used to monitor rapid changes in DNA synthesis. 
Kev words: cancer, polyamines, ODC, DFMO, cell proliferation, flow cytometry, cytokinetics, 
BrdUrd, DNA synthesis, nutrition, TPN, energy state, 31P-NMR. 
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ABSTRACT 
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Departments of Otolaryngology and Surgery, University of Göteborg, Sahlgrenska hospital, 
S-413 45 Göteborg, SWEDEN. 
Ornithine decarboxylase (ODC) is a rate-limiting enzyme for the synthesis of polyamines. 
Polyamines regulate DNA synthesis by a mechanism which is not fully understood. High 
levels of polyamines and ODC activity are associated with rapid cell growth, particularly in tu­
mour tissues. The aim of this study was to evaluate ODC activity as a possible marker for 
rapid alterations in tumour growth and to determine whether this method could be used to estab­
lish whether nutritional support in cancer patients can stimulate tumour cell proliferation. 
Weight-loosing head and neck cancer patients and tumour-bearing mice (MCG 101 C57/BL) 
were studied during different feeding regimens. The ODC activity in tumour tissue was investi­
gated in relation to 1. histopathological differentiation, 2. DNA content , 3. thymidine and 
bromodeoxyuridine (BrdUrd) incorporation into DNA and 4. Ki-67 reactivity. The energy state 
of tumour tissue was determined in vivo with Nuclear Magnetic Resonance-spectroscopy ( 31P-
NMR) and in vitro with high performance liquid chromatography (HPLC). 
After 24 hours of starvation, a significant reduction of tumour growth was demonstrated in 
the experimental tumour, along with a reduction of ODC a ctivity, an accumulation of cells in 
the GoGl phase and a reduction of cells incorporating thymidine or BrdUrd into DNA. The en­
ergy charge of the tumour tissue was reduced compared to freely fed animals. Refeeding after 24 
hours of starvation restored the energy charge of tumour tissue to pre-starvation levels and there 
was a general response of all variables but with different lag phases. ODC activity responded 
rapidly and reached higher than pre-starvation values within 1 h. The magnitude of this response 
to refeeding was related to the carbohydrate content of the food and to the levels of plasma in­
sulin. 
After specific inhibition of ODC with difluoromethylornithine (DFMO) a prolonged poten­
tial doubling time of the tumour was demonstrated. There was a prolonged DNA-synthesis 
time, causing an accumulation of cells in the G2M phase and an increased fractional c ell loss. 
The energy charge of tumour tissue was not reduced. 
Tumour biopsies from head and neck cancer patients demonstrated aneuploidy in 70% of the 
patients and a growth fraction of around 55% of tumour cells. High ODC activity in tumour 
tissue was demonstrated mainly among poorly differentiated tumours and ODC activity was cor­
related to t he proportion of aneuploidic cells in the tumour. High ODC activity may indicate a 
poor short term-survival (one year). 
"Enteral nutrition" to cachectic cancer patients increased the proportion of aneuploidic cells 
in tumours compared to spontaneous feeding. "Parenteral nutrition" did not produce any cytoki-
netic effects in the tumour. 
It was concluded that experimental tumour growth is highly dependent on the host feeding. 
However, there was little evidence to support the fear that nutritional support in cancer patients 
stimulates tumour cell proliferation. ODC is suggested to have a direct role in the induction and 
promotion of cell division. Determination of ODC activity may have prognostic significance 
for survival and can probably be used to monitor rapid changes in DNA synthesis. 
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ABBREVIATIONS 
Frequently used abbreviations. 
BrdUrd Bromodeoxyuridine 
DFMO a-difluoromethylornithine 
FITC Fluorescein isothiocyanate 
HPLC High performance liquid chromatography 
Kcal Kilocalories 
NMR Nuclear magnetic resonance 
ODC Ornithine decarboxylase 
RM Relative movement 
SAMD S-adenosyl-methionine decarboxylase 
TPN Total parenteral nutrition 
V Potential doubling time 
Ts DNA-synthesis time 
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INTRODUCTION 
Progressive malnutrition due to cancer disease is well recognised and 
around 50 % of cancer patients will die with cachexia. This is certainly 
true for head and neck cancer patients, 20-30 % of who exhibit weight 
loss on admission for treatment [1-3]. Furthermore, oncological treat­
ment with surgery, radiotherapy and chemotherapy adds to the 
catabolism of these cancer patients [4,5]. Malnutrition in these patients 
adversely affects survival, the response rate to chemotherapy, subjec­
tive and objective tolerance to treatment and quality of life [1, 6-15]. It 
is recognised that nutritional support in malnourished patients reduces 
postoperative morbidity [15-21] and it is a common clinical observation 
that well-nourished patients have a better ability to sustain their onco­
logical treatment [5]. However, it has not been possible to show any 
effects of nutritional support in cancer patients in terms of reduction of 
recurrence rate or increased survival [15, 22, 23]. It is often feared that 
nutritional treatment in a tumour-bearing host can activate tumour cell 
proliferation, as has been reported for a number of experimental 
tumour systems [24-28]. Such effects of nutritional support in human 
cancer patients are suggested in a recent report [29]. However, if 
tumour cell proliferation is possible to modulate with artificial nutrition 
in human cancer, this knowledge could possibly be used to choose and 
improve oncological treatment [30]. In this context, sensitive methods 
are needed to determine growth characteristics and metabolic changes 
of the tumour. 
At present, the choice of optimal treatment for the individual cancer 
patient is based on a clinical examination, mainly considering the gen­
eral condition of the patient and the tumour stage [31]. The biological 
aggressiveness of the tumour is determined by a routine morphological 
investigation where the cell type, differentiation, infiltration and degree 
7 
of inflammation are considered [13, 32-36]. At several institutions, 
measurements of DNA content have been performed in order to extend 
the biological characteristics of the tumour [37-49]. Such DNA deter­
minations are accomplished after specific DNA staining. By using flow 
cytometric equipment, a considerable number of cells can be rapidly 
analysed. Since there is a progressive increase of cellular DNA content 
through the cell cycle, the relative number of cells in different phases of 
the cell cycle can be demonstrated (Figs 1 and 2, [50, 51]). 
Figure 1: The cell cvcle. The cells cycle through the Gi, S and G2M phases which 
represent cells in the growth fraction. Gi represents cells being "primed" for cell 
growth but not yet DNA synthesising, containing the same amount of DNA as 
cells in quiescence (GQ). During the S phase DNA synthesis occurs and the DNA 
content increases progressively until the cells have double the amount of DNA 
(G2M). Then cell division occurs and the cells reenter the Gi phase or pass into a 
quiescent state (GQ). 
It has been suggested that the DNA content may have predictive 
value for survival in many human cancers and has been used in the 
evaluation of treatment for certain tumour diseases [37, 38, 46, 52-59]. 
DNA analysis and morphology are both methods providing a 
< 
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"snapshot" of the tumour being of a static nature, however, and thus 
provides limited information of the dynamics of cell proliferation [60]. 
G0G1 
Relative 
DNA content 
Figure 2: DNA-histoffram. A DNA histogram can provide information on the rela­
tive DNA content of a tumour. This DNA content can then be put in relation to a 
known standard. Thus, ploidy and occurrence of different cell clones can be deter­
mined. The figure represents a flow cytometric DNA histogram from the MCG 101 
sarcoma used for the experiments in papers I, II and III. Tumours from freely fed 
mice had around 60% of cells in the G(jGi phase, 30% in S phase and 10% in G2M 
phase. The cells below the histogram illustrate the progressive increase in DNA 
content enabling the flow cytometric analysis to be performed after DNA staining. 
Tumour volume and tumour weight reflect the net result of tumour 
growth [24, 61, 62]. Tumour growth rate, however, is dependent on 
the relative size of the growth fraction of tumour cells, the rate of cell 
cycle transfer and the cell loss [63-67]. Determination of the incorpora­
tion of various precursors into DNA has given further insight into the 
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cell kinetics of tumour cells [68-72]. This has been accomplished using 
tritiated thymidine and analysis with autoradiographic and scintillation 
techniques, which are time-consuming assays. Bromodeoxyuridine 
(BrdUrd) is a thymidine analogue possible to analyse immunohisto-
chemically or with the flow cytometric technique, providing more de­
tailed cell kinetic information on tumour growth [65, 73, 74], 
The ideal method of assessment of tumour growth would be both 
easy to monitor in clinical practice and allow detection of rapid changes 
of cell proliferation. During recent years, polyamines (Fig. 3) have 
attracted the interest of many investigators, since the growth rate of 
rapidly growing tissues is related to polyamine synthesis [75-79]. 
Polyamines are involved in the regulation of DNA synthesis and cell 
division, although their exact function is not completely understood 
[80]. The activity of RNA polymerase and protein and DNA synthesis 
are reported to be stimulated by polyamines in a variety of experimental 
systems [75, 81-84], The role of polyamines for cell growth has been 
confirmed in several clinical studies. Accordingly it has been demon­
strated that urine polyamine levels correlate with the tumour burden of 
the host [85, 86] and elevated levels of polyamines have been found in 
sera from patients with advanced solid tumours [87]. Increased levels 
of polyamines have been demonstrated in tumour tissue from oral, 
breast and colorectal cancers [88-92]. Studies of polyamine levels in 
cerebrospinal fluid have been used to determine proliferative activity of 
certain brain tumours [93]. Furthermore, polyamine levels were in­
creased in erythrocytes from a group of cancer patients receiving intra­
venous nutrition compared to a non-cancer control group [94], 
10 
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DNA-synthesis 
Figure 3. 
A schematic illustration of the polyamine synthesis pathway. The polyamines pu­
trescine, spermidine and spermine are present in all mammalian cells and are known 
to be essential for DNA synthesis in cell growth, although their exact function is 
unknown. The synthesis of putrescine is regulated by the availability of ornithine 
and the activity of ornithine decarboxylase (ODC; EC 4.1.1.17). The other 
polyamines are derived from putrescine by the action of spermidine synthase (EC 
2.5.1.16) and spermine synthase (EC 2.5.1.22) which both require decarboxylated S-
adenosyl-methionine, leaving an aminopropyl-group (5MTA = 5 methylthioadeno-
sine). The second rate-limiting enzyme of this pathway is S-adenosyl-methionine 
decarboxylase (SAMD; EC 4.1.1.50) 
Note the interaction steps of ODC and SAMD in the figure. The rate of 
polyamine synthesis can be determined by the activity of ornithine decarboxylase, 
which is assessed by the rate of CO2 release under optimal in-vitro conditions. 
Polyamine synthesis is dependent on the availability of ornithine and 
the activity of ornithine decarboxylase (ODC) [77, 95-97]. ODC-activ-
ity is generally increased in tumour tissue compared to normal tissues 
in both experimental [75,76, 98] and human cancer [99-103]. Absence 
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of ornithine or ODC results in a retardation of tumour growth since 
tumours need polyamines for normal DNA synthesis [77]. ODC is 
rapidly activated by proliferative stimuli and is characterised by an 
extremely rapid turnover of about 10-20 minutes [77, 104-113]. 
Determination of ODC activity directly from tumour tissue will reflect 
polyamine metabolism and can possibly be used to monitor acute 
changes in tumour cell proliferation. 
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THE AIMS OF THE STUDY 
The specific purpose of this study was; 
• to evaluate whether refeeding after 24 h of starvation activates 
ornithine decarboxylase (ODC) in an experimental solid tumour 
and, if so, which component (carbohydrate, fat, protein) in the diet 
re-establishes the ODC activity (I). 
• to study how ODC activity and starvation-refeeding influence 
tumour cytokinetics of the experimental tumour in vivo (II). 
• to determine whether changes in ODC activity or starvation-
refeeding modulate tumour growth by acute alterations of the 
energy state in the experimental tumour (HI). 
• to investigate whether nutritional support stimulates tumour cell 
proliferation in weight-loosing patients with head and neck cancer 
(IV,V). 
13 
MATERIAL 
Patients 
Altogether forty patients with various head and neck cancer tumours 
were examined (IV,V). Their clinical data and nutritional status are pre­
sented in Table 1. There were 30 men and 10 women with a mean age 
of 66 years (46-85). All patients had a recent history of > 5 % weight-
loss. The diagnoses were oral carcinoma 27, hypopharyngeal carci­
noma 8, laryngeal carcinoma 2, maxillary carcinoma 2 and salivary 
gland carcinoma one. Most of the patients had advanced tumours (T4, 
n=24; T3, n=6; T2, n=10). All but four tumours were histologically 
classified as squamous cell carcinomas of which 15 were poorly differ­
entiated and 21 were moderately or well differentiated. The remaining 
four tumours were one malignant fibrous histicytoma, one malignant 
non-Hodgkin lymphoma, one Hodgkin lymphoma and one anaplastic 
cancer. Patients with other diseases, such as diabetes or heart failure, 
were excluded from the study. None of the patients had received any 
kind of cytostatic treatment, radiotherapy, anti-inflammatory drug or 
hormonal substitution prior to the investigations. 
Nutritional status was determined as follows: Body weight index 
was calculated as the actual weight divided by the reference weight for 
height [20, 114] Normal weight index was > 0.80. Arm circumfer­
ence, considered to be an anthropometric measure of proteins in the 
body and triceps skinfold considered to be an index of lipid stores were 
measured at the midpoint of the left arm. The arm muscle circum­
ference (AMC) was then calculated and compared with a reference 
population [115]. Serum albumin was analysed using the hospital's 
routine colour binding procedure. Low values were < 33 g/1 fo r 
women and < 36 for men [20]. Total body potassium (TBK) was 
14 
No. Sex Age Diagnosis Diff. Classification Weight Weight AMCAlbumin Total K+ 
T N M loss % index cm Kfi mmol 
1 M 55 oral poor 4 3 0 10 0.67* 21.4* 38 2544* 
2 M 80 oral mod 2 0 0 10 0.97 29.5 33* 3204* 
3 M 63 oral mod 2 0 0 5 0.73* 23.9 43 2911* 
4 M 64 hypoph. poor 4 0 0 10 0.63* 23.1 37 2925* 
5 M 58 oral Histioc. 4 0 0 13 0.91 28.6 37 4084 
6 F 59 oral poor 4 0 0 5 0.91 28.7 - 2697 
7 M 57 hypoph. high 4 1 0 20 0.60* 23.4 34* 2899* 
8 M 84 hypoph. mod 3 2 0 12 0.63* 21.1 43 2368* 
9 F 65 submand. mod 4 1 0 5 0.68* 21.1 37 1879* 
10 F 59 oral poor 4 1 0 5 0.60* 19.9* 32* 1623* 
11 M 68 oral mod 4 1 0 5 0.77* 24.6 39 2778* 
12 M 65 oral mod 4 1 0 5 0.77* 23.5 42 2897* 
13 F 65 hypoph. poor 4 1 0 8 0.74* 28.0 40 2344* 
14 F 61 oral poor 4 0 0 7 0.96 29.1 39 -
15 M 46 oral Hodgkin 4 3 1 13 0.74* 25.1 39 3434 
16 F 85 oral high 2 0 0 5 0.68* _ 45 2116* 
17 M 69 hypoph. poor 4 1 0 5 0.81 25.9 45 3067* 
18 M 64 oral Anapl. 3 0 1 5 0.78* 23.1 37 2998* 
19 M 60 oral mod 2 0 0 5 1.05 26.3 42 -
20 M 61 oral poor 4 2 0 14 0.82 26.8 37 3141* 
21 M 67 oral mod 3 3 0 5 0.84 28.9 40 3516 
22 M 54 oral mod 2 1 0 5 0.76* - 41 -
23 M 81 oral mod 4 2 0 5 0.88 29.5 40 3156* 
24 M 67 hypoph. high 4 0 0 5 0.68* 20.8* - -
25 M 69 maxill. poor 4 1 0 15 0.95 27.1 34* 3678 
26 M 61 oral poor 4 1 0 5 0.77* 27.7 38 2448* 
27 M 68 oral poor 2 1 0 5 0.91 26.6 40 3629 
28 F 71 oral mod 3 0 0 5 0.77* 24.7 38 2161* 
29 M 55 larynx poor 2 1 0 5 0.94 - 46 4217 
30 M 79 oral Lymphoma 3 1 0 5 0.85 - - -
31 M 54 larynx mod 4 1 0 5 0.89 
- - -
32 M 74 oral poor 4 0 0 5 0.95 28.5 31* 2840* 
36 F 62 hypoph. poor 4 0 0 20 0.48* 18.4* 40 1840* 
38 M 75 oral poor 3 0 0 8 0.78* 23.5 38 2880* 
33 M 52 oral mod 2 0 0 8 0.82 28.2 32* 2890* 
34 M 46 maxill. mod 4 0 0 8 0.73* 25.2 36* 3880 
35 F 82 oral mod 4 1 0 5 0.73* 22.0 39 2150* 
37 M 67 hypoph. mod 2 0 0 15 0.75* 21.0* 41 2560* 
39 F 77 oral mod 2 1 0 5 0.92 22.4 38 2260* 
40 M 72 oral mod 4 0 0 10 0.96 28.8 46 3510* 
Table 1. 
Clinical data and nutritional status of patients in this study. Patients no. 1-15 are 
the study group ("enteral nutrition") and no. 16-31 the control group in paper IV. 
Patients no. 32-40 are the study group ("intravenous nutrition") in paper V. 
* = pathological value compared to a reference population. 
determined measuring the natural 40K emission in a whole body 
counter as described in paper V [116]. 
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Animal model 
The tumour-bearing animal model used in this study (I,H,III) has been 
extensively used in our laboratory and is well characterised [117-122], 
Three months old, weight stable (20-25 g), sex matched male and 
female mice (C57B1/6J, Bomholtgård, Ry, Denmark) were used 
throughout. A poorly differentiated sarcoma (MCG 101), originally 
induced with methylcholanthrene, was used as an isogenic tumour 
graft. The tumour was transplanted subcutaneously in the flanks under 
aseptic conditions. The tumour does not penetrate the abdominal wall 
or metastasise. Its influence on the host metabolism has been evaluated 
in a series of reports [119, 123-125]. The tumour is palpable after 5-7 
days and demonstrates an exponential growth rate until the tumour-
bearing mice die with cachexia 15-17 days after tumour implantation 
[24, 62]. Anorexia is demonstrable from day 6-7 and the cachectic 
reactions of the host to the tumour are considered to be similar to those 
observed in clinical cancer [123, 126]. 
Most experiments were performed 8-10 days after tumour implanta­
tion, when the tumour size was approximately 1 gram. The animals 
were kept in individual cages with coarse sawdust bedding with free 
access to a Purina chow diet and tap water unless otherwise stated. The 
ambient temperature was 25-26°C and the mice were kept on a 12 h 
light/12 h darkness schedule. Body weight, tumour weight, food in­
take and water intake were registrated regularly throughout the experi­
ments. The animals were killed by cervical dislocation. For every 
tumour-bearing animal studied, a corresponding control animal was 
killed simultaneously. 
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STUDY DESIGN 
Clinical studies (IV,V) 
All consecutive patients with head and neck cancer and a recent history 
of weight loss > 5 % were invited to take part in the studies. Initial 
tumour biopsies were taken after an overnight fast. They were taken 
from apparently viable tumour tissue and were then subjected to histo­
logical examination and analysis of flow cytometric DNA content, 
ODC activity (IV,V) and Ki-67 reactivity (V). One tissue sample was 
also taken from the normal mucous membrane in the oral cavity for 
control measurements in the various assays. The patients in paper IV 
were randomised into a control and a study group. The study patients 
received enteral nutrition (Clinifeed Protein rich®, Roussel Nutrition, 
Stockholm, Sweden) by means of a nasogastric tube (IV). Harris-
Benedict's formula was used to estimate the patients resting energy ex­
penditure [127]. An energy content corresponding to 150 % of resting 
energy expenditure was given as non protein calories (2675±59 and 
2055±71 Kcal for men and women respectively) and proteins (0.8 to 
1.0 g/kg/day) to the study group of patients. The study patients in 
paper V received the same energy and protein content as above but by 
means of artificial intravenous nutrition (TPN). The control group of 
patients were allowed to eat according to their spontaneous appetite. 
This means a caloric intake estimated to be less than 1000 Kcal/day and 
0.5 g protein/kg/day even though the patients were hospitalised (IV, 
[3, 128]). 
After 6-8 days of nutritional support, a second sample of tumour 
tissue was taken from all study and control patients as far as possible 
from the location of the first biopsy, in order to avoid tissue reactions 
from the the injury of the first biopsy. 
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Informed consent was obtained from all patients taking part in this 
study, which was approved by the Committee for Ethics of the Faculty 
of Medicine, University of Gothenburg, Sweden. 
Experimental studies (I,II,III) 
Starvation and Refeeding fI.II.IIP 
All animals were fed ad libitum with a Purina chow diet unless other­
wise indicated. Starvation for 24 hours was used in order to study 
tumour growth retardation. Refeeding with Purina chow was instituted 
in several experiments after a period of 24 h starvation (I,II,III). In 
some experiments, various deficient diets were used for refeeding (I). 
Inhibition of QDC activity d.II.III) 
a-difluoromethylornithine (DFMO) is a specific irreversible inhibitor 
of ODC [77, 82, 129-133]. It was kindly supplied by the Merrell Dow, 
Research Institute. Strasbourg, France. The effects on tumour growth 
were studied after inactivation of ODC with DFMO (I,II,III). DFMO 
was diluted with tap water (2%) and given from the 3rd day after 
tumour implantation until death. DFMO treatment did not affect water 
or food intake. 
Insulin experiments (I) 
Insulin experiments were performed to study whether insulin mediated 
the nutritional regulation of tumour ODC activity. Plasma insulin of the 
animals was measured by a double antibody technique (Novo) and 
plasma glucose was measured by the glucose oxidase method (kit from 
Boehringer, Mannheim) as described in detail elsewhere [134], The 
plasma insulin response to refeeding was blocked by pretreatment with 
anti-insulin antibodies (I). These antibodies were shown to block the 
immune-recognising epitope on circulating mouse plasma insulin 
molecules, since insulin levels were undetectable in anti-insulin 
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tumour-bearing animals but not in sham-injected refed tumour-bearing 
controls. To ascertain that anti-insulin antagonised insulin's biological 
activity, glycerol release in a bioassay system with incubated rat epi­
didymal fat cells was used as an index of the plasma sample's lipolytic 
activity [135]. 
Inhibition of protein synthesis (I) 
Protein synthesis was inhibited to study whether changes in ODC 
activity were related to de novo synthesis of the enzyme protein. 
Cycloheximide is known to be an inhibitor of protein synthesis at the 
translational level [136,137]. Tumour and hepatic protein synthesis of 
the animals was inhibited by intraperitoneal administration of 0.5 mg 
cycloheximide per g body weight. This dose was chosen since it was 
not lethal in any case. The possibility of a direct toxic influence of 
cycloheximide on the ODC assay could be excluded as shown by in-
vitro experiments, since no direct influence on the enzyme could be 
demonstrated with different concentrations of cycloheximide in the in­
cubation medium (I). 
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METHODOLOGICAL CONSIDERATIONS 
In this study, ODC activity has been related to the findings of biochem­
ical, flow cytometric and immuno-histochemical assays, as well as to 
the energy state of the tumour determined in vivo and in vitro. 
Enzyme assays (I-V) 
Homogenisation of tissue was performed in a sucrose buffer freshly 
made before each experiment. Centrifugation was performed at 
40000xg for 2 hours in order to remove mitochondria, where enzymes 
can be located that may generate labelled CO2 which are irrelevant for 
the ODC assay [138]. After centrifugation, the protein content of the 
supernatant was determined as described by Lowry [139]. The super­
natant could then be s tored at -70°C for one month before enzyme 
assay. The activity was shown to be stable during this time. There is a 
known diurnal variation of ODC activity in tissues [140, 141], proba­
bly due to variations of dietary intake. In order to avoid this diurnal 
variation of ODC activity, all experiments were started at 8 am in the 
morning and there were always control animals killed simultaneously 
with the study animals. 
Ornithine decarboxylase ("ODC) 
ODC activity of the sample was determined in duplicate by measuring 
the release of 14C02 from an ornithine-saturated buffer containing Re­
labelled DL-ornithine, The method used is a slight modification of the 
method described by Noguchi et al [142], Scintillation counting was 
performed with an LKB Wallac 1215 Racbeta II Liquid scintillation 
counter, to give the released 14C02 /h. The tissue activity of ODC could 
then be expressed as nmoles CO2 /h/mg protein. 
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S-adenosvlmethionine-decarboxvlase (SAMP) 
S AMD activity was analysed with a procedure very similar to that 
described for ODC, using labelled S-adenosylmethionine14C (I). The 
method is described in detail by Pegg and Pösö [143], 
Polyamine assay (I) 
The polyamine content in tumour, liver, spleenic and intestinal tissues 
was determined with high performance liquid chromatography (HPLC) 
as described by others [144], The poly amines were separated with a 
Nova-Pak CI8 column using an automatic sample injector (WISP 
710B, Waters Chromatography Division, Millipore Corporation, 
Milford, USA). 
Protein synthesis (I) 
Protein synthesis was estimated using the flooding technique originally 
described by Garlick [145] The flooding dose of 14C-U-leucine was 
injected i.p. and the animals were killed 30 min. later. Tissue protein 
was extracted and radioactivity in proteins was determined as described 
elsewhere [146]. 
Flow cytometry (II,IV,V) 
Flow cytometry was used to determine the relative size of the cell cycle 
compartments and for assay of labelled cells after incorporation of 
BrdUrd into DNA. Flow cytometry was also used to determine the 
relative size of the aneuploidic compartment in the human tumours 
studied. 
For cytokinetic analysis of the experimental tumour, a single cell 
suspension was obtained by mincing the tumour tissue in a buffer 
solution containing collagenase (II,III). The trypan blue exclusion test 
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showed a cell viability in this solution of more than 90 % [147]. After 
denaturation of the double stranded DNA, the BrdUrd incorporation 
into DNA could be visualised by staining with fluorescein isothio-
cyanate (FITC)-conjugated BrdUrd. Furthermore, DNA content could 
be assessed after staining with propidium iodide. Measurements were 
performed with an MPV Flow cytometer (Leitz) attached to a Monroe 
8888 computer system. Both fluorochromes were excited by the 395 -
495 nm interval light from a mercury source. Emission of propidium 
iodide and FITC-fluorescence was measured above 610 nm and in the 
interval 510 to 540 nm respectively. 
A tumour sample of 100-200 mg was taken from 3 different loca­
tions of viable tumour for analysis of the human tumours (IV,V). The 
preparation was then processed according to Barlogie et al [148], The 
sample was analysed with an ICP 11-PHYWE pulse cytophotometer 
(Göttingen, Germany) with human leucocytes as a standard. On aver­
age 20 000 - 30 000 cells from each sample were measured, with a co­
efficient of variation (CV) < 5%. 
Ki-67 reactivity (V) 
The monoclonal antibody Ki-67 is known to be directed against a pro­
liferation-associated antigen present in the nuclei of proliferating cells 
[149, 150]. Thus, the growth fraction of tumours was determined from 
samples snap frozen in liquid nitrogen. Acetone and chloroform were 
used for fixation to preserve the antigen. After staining with Ki-67 
using the immunoalkaline phosphatase anti-alkaline phosphatase 
(APAAP) technique as described previously [151, 152], tumour cells 
could be evaluated for nuclear staining (V). The percentage of stained 
tumour cells correlated significantly (r=0.86; pcO.Ol) with the number 
of aneuploidic cells in the replicative phases S+G2M. 
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Thymidine incorporation (I) 
The rate of DNA synthesis can be estimated from the rate of incorpora­
tion of labelled thymidine into DNA [69, 153]. The mice were injected 
intraperitoneally with a single dose of 14C-thymidine one hour before 
death (I). Tumour tissue was immediately frozen in liquid nitrogen and 
placed in a -70°C freezer. Within one week DNA extraction was per­
formed after homogenisation of the tumour tissue. DNA concentration 
was determined with calf thymus DNA as the standard [154]. The 
radioactivity of the sample was determined in triplicate by scintillation 
spectrometry. 14C-labelled thymidine was chosen instead of tritiated in 
order to obtain stable scintillation counts. The specific radioactivity and 
hence the rate of thymidine incorporation into DNA/h, was calculated 
per mg DNA. 
Bromodeoxyuridine incorporation (II,III) 
Bromodeoxyuridine (BrdUrd) is a thymidine analogue and was used to 
measure DNA-synthesis in terms of BrdUrd incorporation into DNA. 
Cells incorporating BrdUrd into DNA are considered to be actively 
DNA-synthesising cells [60, 68, 72, 155, 156]. This technique can be 
combined with flow cytometric analysis of DNA content to obtain more 
detailed information on the cell cycle kinetics [65, 70, 71, 157, 158]. 
Tumour-bearing animals were injected i.p. with 0.1 mg BrdUrd/g 
body weight [159] as a single injection. Higher doses failed to label a 
larger percentage of cells suggesting that the chosen dose was suffi­
cient to label all cells, capable of incorporating BrdUrd into DNA. This 
in-vivo labelling technique was more efficient and reliable than in-vitro 
labelling using an incubation medium containing BrdUrd. The in-vitro 
incubation gave a 40 % reduction in the yield of BrdUrd-labelled cells 
compared to in-vivo labelling. Furthermore, by using the trypan blue 
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exclusion test, we noted 30% non-viable cells in the cell suspension 
after in-vitro incubation and <10 % non-viable cells after in-v ivo 
labelling. By means of tritiated BrdUrd, we found in separate experi­
ments that only 4 % of of the tritiated BrdUrd remained in plasma after 
one hour. There was a positive correlation between the relative S-phase 
compartment size (flow cytometry) and immunocytochemically deter­
mined BrdUrd incorporation into tumour DNA (r = 0.81, not shown). 
There was no change in ODC activity or the relative size of the S-phase 
compartment, after repeated injections of BrdUrd performed in some 
experiments, suggesting that there was no cytotoxic effect of the 
BrdUrd dose. 
Immunocvtochemical staining for BrdUrd. 
Monolayered cytospin preparations of tumour cells were made with a 
Shandon 2 cytocentrifuge. The slides were fixed in 70 % ethanol for 
lh and allowed to dry. DNA was then denatured and cells in the S-
phase were visualised after incubation with an anti-BrdUrd monoclonal 
antibody (Becton Dickinson Svenska AB, Hagersten, Sweden) and a 
peroxidase-conjugated secondary antibody (Dakopatts AB, Hagersten, 
Sweden) developed with diaminobenzidine as a chromogen. The per­
centage of labelled cells was determined by counting 500 cells 
(leucocytes omitted) under an ordinary light microscope. With this 
method, nuclei containing even small amounts of BrdUrd can be de­
tected. 
Staining for combined flow cytometric analysis of BrdUrd and cellular 
DNA content. 
After ethanol fixation and DNA denaturation, the cells were incubated 
with an anti-BrdUrd monoclonal antibody. Then followed incubation 
with an FITC-conjugated secondary antibody. Cellular DNA was 
stained with propidium iodide. The amount of BrdUrd-labelled cells in 
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the different cell cycle compartments could be determined, since the 
staining procedure with propidium iodide for DNA content and the 
FITC-conjugated antibody for BrdUrd labelling were performed on the 
same sample,. 
Cytokinetic evaluation (II) 
The cell proliferation rate of the tumour cannot be deduced from 
tumour weight or volume measurements only, since the impact of cell 
loss and non-dividing cells must also be accounted for. Flow cytome­
try only provides a static picture of the distribution of DNA-content, 
illustrating the relative size of the cell cycle phases at the time of 
biopsy. Thus, flow cytometry and Ki-67 reactivity do not provide suf­
ficient information to assess the cell cycle dynamics. By labelling the 
DNA-synthesising cells with BrdUrd and then using flow cytometry, it 
is possible to observe the labelled cells through the cell cycle and cell 
division, facilitating evaluation of the cytokinetics of tumour growth. 
All cytokinetic determinations are based on the assumption that the rate 
of cell cycle traverse is constant in all cell cycle phases. 
Graphic estimation of DNA synthesis time. 
In order to obtain the DNA synthesis time (Tg) of an exponentially 
growing cell culture, Sasaki suggested that serial labelling indices can 
be plotted against the corresponding times of incubation with a 
BrdUrd-containing medium [73]. The slope of the regression line ob­
tained makes it possible to calculate Ts, assuming that the Gi cells enter 
the S phase at a constant rate. This graphic method designed for 
assessment of growing cells in a cell culture was modified in the pre­
sent study to enable estimation of Ts after in-vivo labelling with 
BrdUrd as described above. 
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Figure 4. 
Illustration of the graphic method described by Sasaki for obtaining DNA-synthesis 
time. A modification of this method was used for the estimations in table 2 (II) 
where the relative size of the S-phase compartment as determined by flow cytometry 
was plotted at time 0 hours. At time 9 hours after BrdUrd injection, the plotted 
value is the sum of the percentage of FITC fluorescence in GoGi of cells having 
passed through the S phase after the BrdUrd injection i.p. (see formula I in paper II) 
plus the percentage of cells in the S phase as determined by flow cytometry. DNA-
synthesis time is the negative intercept of the extrapolated regression line (7.410.5 
h for freely fed animals). This graphic estimation was performed for 8 animals in 
each of the study groups and the results given in paper II represent the mean values. 
The potential doubling time (Tpx) can also be determined graphically, 
as shown by Okada [160]. Tjxjis defined as the time the tumour takes 
to double its cell content being capable of continuous proliferation. 
26 
100 
90 
80 
70 
G 1=63% 60 Tn„, = 9.2+7.4+2.9 = 19.5 h 
50 
S=27% 
20 
10 
G2M=10% S=7.5 hours 
0 
G1=9.2 h G2M=2.9 h 
Time (h) 
Figure 5 
Illustration of the graphie method described by Okada for computing the parameters 
of the life cycle of cultured cells in the exponential growth phase. This figure shows 
the graphic estimation from a tumour from one of the animals of figure 4. The rela­
tive size of the cell cycle phases is known from flow cytometry. The duration of the 
S phase is also estimated (Ts=7.5 from Fig 4) giving the X-axis a time scale. The 
entire cell cycle time can then be estimated as shown in the figure. 
Relative movement of BrdUrd-labelled cells. 
An alternative method of determining the time of DNA synthesis (Ts) of 
the tumour from a single sample of BrdUrd-labelled cells was sug­
gested by Begg [65]. The analysis is based on measurements of the 
relative movement (RM) of labelled cells in cell cycle transit as illus­
trated in chart 1 and described in paper II [65]. The calculation of cell 
cycle progression is based on the assumption that the entire DNA-syn-
thesis time is 1.0 and that the mean value of fluorescing label is 0.5 at 
the time of injection of BrdUrd. In this study, the relative movement 
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(RM) of the mean fluorescesence of BrdUrd-labelled cells was then 
determined 1/2, 1, 2 and 4 h after injection of BrdUrd and plotted 
against time, to give the DNA synthesis time (T^ in which RM reaches 
unity =1.0 (Fig. 6). 
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Figure (>, 
Relative movement (RM) of BrdUrd-labelled cells. It is assumed that the mean fluo­
rescence of the label is 0.5 at time zero (Tq), and that the entire duration of DNA 
synthesis is 1.0. The mean fluorescence of the label is plotted against time after 
BrdUrd injected at To. RM is calculated for each observation according to Begg [65] 
and a regression line is constructed. Each point represents the mean of 6 obser­
vations and bars represent SEM. Note the intercept of the extrapolated regression 
line around 420 minutes = 7 hours when RM reaches unity at 1.0. Thus the 
duration of DNA synthesis is estimated graphically to be Ts = 7 hours. 
Since the initial value of RM at t=0 is 0.5 and RM at a time (t) is very 
near a linear function of time, a single measurement at some time (t) 
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can be used together with the initial value to obtain Ts [65, 74], This 
assumption is supported by the results shown in figure 4. However, a 
non-linear plot must be expected in an expanding tumour cell popula­
tion since cells in the S phase will then have a non-linear age distribu­
tion. This means that there will be more cells at the beginning of the S 
phase. Furthermore, the length of the G2M phase relative to the S 
phase can affect the RM versus t plot, creating a curvature of the plot 
[65, 74]. The impact of these effects can be corrected for when estimat­
ing Ts from only one sample [65, 74], However, in the experiment 
shown (Fig. 6) the regression line is based on 24 observations in all, 
so that no such correction was necessary. 
Fractional new cell formation. 
Repeated injection (pulses) of BrdUrd every second hour (Oh, 2h an d 
4h) facilitates estimation of the fraction of new cells entering the S 
phase (FRn^v from formula III in paper II), if the progression of cells 
through the S phase is constant, as assumed above. Immunocyto-
chemical staining with peroxidase enables the labelling index to be 
determined after 1 h and 6 h respectively. The difference in labelling 
index equals the fractional new cell formation (II). 
Another way to determine the fractional cell transit is by calculating 
the fraction of cells which have passed through the S+G2M phases 
through cell division and entered the G(jGi phase. This has been done 
by using the bivariate flow technique 9 hours after pulse labelling. The 
proportion of FITC-labelled cells per hour entering the GqGi phase 
(FRhic) can then be estimated from the formula below (II): 
F G0G1 
^ FITC -
G0G1 G0G1 
+ 
FSG2M j x t 
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The fluorescence in GQGI (FG OGI) must be divided by 2 because 
these cells have undergone cell division. The rate at which BrdUrd-
labelled cells enter GDGI (F RPNC) IS thus expressed as the amount of 
fluorescence in Gc)Gi in relation to the total amount of fluorescence. 
The potential doubling time of the tumour can then be estimated as 
described in paper II (formula II). 
Cell loss. 
The DNA-synthesis time and the potential doubling time describe the 
dynamics of the cell cycle but the virtual tumour growth rate is also 
dependent on cell loss during cell replication [63, 64, 65, 67]. Begg 
suggested estimation of cell loss by relating Tp* to measurements of the 
volume doubling time of the tumour [65]. The volume doubling time of 
the tumour, however, needs to be measured during an observation 
period and serial volume registrations are required [61]. In the present 
study, an alternative measure of cell loss has been obtained by subtract­
ing the fractional new cell formation (FRpjjc) as determined by the 
bivariate flow technique from the percentage increase of the peroxi-
dase-stained cells (FRpex). FRpe* was calculated by subtracting the 
labelling index after lh from the corresponding index after 9h (II). This 
estimate of fractional cell loss is based on the assumption that the per­
oxidase technique only accounts for stained cells with a preserved 
nuclear structure, while the FITC technique cannot distinguish between 
viable and destructed cells as long as the fluorescing material has a 
nuclear content within the range of the DNA histogram (II; chart 1). 
When the potential doubling time is taken into account, the actual cell 
loss per cell division can be calculated as described in paper II (formula 
IV and V). 
30 
Energy state of tumour tissue (III) 
The energy state of the tumour tissue was determined in order to exam­
ine whether changes in ODC activity and cell proliferation rate were 
correlated to changes in energy state. In recent years, the energy state 
of living tissue has been possible to establish in vivo by analysis of 
phosphorus metabolites using nuclear magnetic resonance spec­
troscopy, 31P-NMR [161-169]. Since phosphorus-containing com­
pounds play a key role in the energy metabolism of tissues, knowledge 
of their relative concentrations in high and low energy phosphorus 
metabolites give insight into the energy state of the tissues [163]. In the 
present study, Nuclear Magnetic Resonance (31P-NMR) measurements 
were performed in vivo and they were then compared with in-vitro 
measurement using high performance liquid chromatography (HPLC). 
Nuclear Magnetic Resonance ft'P-NMR) 
In-vivo measurement of the energy state of tumour tissue by NMR-
spectroscopy was performed on a Bruker Biospec, BMT 24/30. 
Anaesthetised mice were placed with the tumour in a Helmholz coil, 2 
cm diameter. The mice remained in this position for around 10 minutes 
until the 31P-NMR-spectra were obtained. The physical principles 
involved in obtaining an NMR-spectrum from a tissue are described 
elsewhere [170, 171] The relative amount of the metabolites phospho-
creatinine (Per), inorganic phosphate (Pi), adenosinetriphosphate 
(ATP=ßATP), phosphomonoesters (PME) and phosphodiesters (PDE) 
was calculated and expressed in relation to the total phosphorus area. 
The equipment used is presented in paper III and it is considered to 
have a good resolution for assay of the phosphorus compounds [172], 
The great advantage of using 31P-NMR-spectra for determination of 
changes in energy state of tissues is obviously the possibility of per­
forming repeated measurements on the same individual. This technique 
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certainly has a promising future for assessment of changes in 
metabolism as a response to various treatments in human cancer [161, 
165, 167, 173-175]. 
High Performance Liquid Chromatography 
In-vitro measurements of the energy state of tumour tissue were per­
formed with an HPLC manufactured by Pharmacia Fine Chemicals 
AB, Uppsala, Sweden [176]. Analysis of the energy metabolites such 
as adenosinetriphosphate (ATP), adenosinediphosphate (ADP), 
adenosinemonophosphate (AMP), inosine (In), hypoxantine (Hx), 
inosinemonophosphate (IMP), uric acid (Ua) phosphocreatinine (Per) 
and creatinine (Cr) could then be performed in fimoles/gram dry weight 
of tumour tissue. This procedure was performed to verify the results 
from the 31P-NMR-spectra used for these experiments [177]. 
Energy State of tumour tissues 
The energy state of tissues was assessed by the relative concentrations 
of high energy phosphates (ATP, PCr) and low energy phosphates 
(PME). The PCr/Pi ratio is often used as an index of the energy state or 
the metabolic respiratory activity of tissues [172], The NMR technique 
and the HPLC technique are not directly comparable because NMR in 
vivo mainly determines cytosolic phosphorus compounds. We have 
therefore, chosen to report the data from both (III). Low energy 
phophates measured with HPLC are ADP,AMP,IMP and inosine. 
The bioenergetic state was expressed as the energy charge of the tis­
sue calculated according to Atkinson [163, 178, 179]. 
Energy charge = 
ATP + ADP + AMP 
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The energy charge is considered to be an equilibrium for energy 
production/utilisation and can be defined as the extent to which the 
adenylate system is filled with high energy phosphates. The ratio 
described varies between 0 and 1.0. If all the adenylate system is in the 
form of ATP, the energy charge will be 1.0. Ordinary living tissue in a 
steady state generally exhibits an energy charge of 0.85. 
Statistics 
Differences between two groups were compared by means of Student's 
t-test or Fischer's exact test [180]. One factor factorial ANOVA with or 
without repeated measures was used for multiple group comparisons. 
Results are given as mean ± SE; a 95% confidence interval was used in 
ANOVA computations; p<0.05 was considered statistically significant. 
The rank sum test was used to test differences in survival in DFMO-
treated animals compared to control animals. 
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RESULTS AND DISCUSSION 
Food intake is one of the most powerful modulators of tumour growth 
in several experimental systems [24-28, 181-183], although not 
consistently so [184, 185]. Nutritional effects on tumour growth have 
been difficult to confirm in human cancer [23], although there was a 
recent report suggesting altered cell cycle kinetics after total parenteral 
nutrition (TPN) in head and neck cancer patients [29]. The risk of 
tumour growth enhancement is important to consider when deciding 
whether a cancer patient should receive artificial nutrition as part of the 
oncological treatment or as palliation treatment only [30, 186, 187]. 
The aim of this study was to identify growth-associated changes in 
tumour tissue in an experimental tumour model in response to 
nutritional modulation and to determine whether nutritional effects on 
tumour growth are demonstratable in human cancer. 
ODC activity in tumour tissue has been determined and studied in 
relation to tumour growth (I-V). ODC has been demonstrated to be 
rate-limiting for the synthesis of polyamines, which play an important 
role in the regulation of DNA-synthesis and cell growth (Fig.3, [75-
77, 78, 81-83, 95, 188]). Several studies have reported elevated 
polyamine levels in human tumours [88-92, 103, 189]. Furthermore, 
elevated polyaminelevels have been reported in urine, cerebrospinal 
fluid, plasma and erythrocytes of cancer patients and such observations 
may be consistent with rapid growth of malignant disease [85-87, 93, 
94, 190-194], 
We have determined ODC activity directly in tumour tissue from 
untreated and malnourished patients with head and neck cancer. A 
recent report demonstrates elevated polyamine levels in squamous cell 
carcinoma of the oral cavity and a variable ODC activity from the same 
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cancers [92], and the degree of differentiation in the tumours has been 
suggested to be related to polyamine content and ODC activity [102]. 
In the present study it was obvious that high levels of ODC activity 
were associated with poor differentiation and a correlation between 
ODC activity and the percentage of cells demonstrating aneuploidy 
(aberrant DNA content) was found (IV). Previous studies have shown 
that the presence of aneuploidy is an unfavourable predictor for the sur­
vival of cancer patients [37, 38, 46, 52-54, 57, 58]. We found that 
70% of the patients demonstrated aneuploidic cell clones (IV and V, 
[37, 39, 54]). However, there was no significant increase in mortality 
within one year among patients demonstrating aneuploidy in their 
tumours, in contrast to cancer patients with high levels of ODC activity 
in tumour tissue, which had significantly shorter survival than others 
(IV). This suggests that high ODC activity in tumour tissue is associ­
ated with an aggressive cancer disease. 
In order to obtain information about the tumour-cytokinetic effects 
in relation to nutritional modulation and ODC activity we used a well-
known tumour model. This model consists of tumour-bearing mice 
with a poorly differentiated, transplantable subcutaneous sarcoma, 
which has been well characterised in our laboratory for several years 
[117-122], The metabolic host reactions in response to the tumour are 
similar to those of cancer patients with progressive cachexia [123, 
126]. The tumour comprised about 5% of the total body weight at the 
time of most of the experiments in this study. The cytokinetic data 
obtained from this rapidly growing experimental tumour model with a 
monoclonal appearance cannot be directly extrapolated to the clinical 
situation, since human cancer demonstrates a considerably slower 
growth rate and generally exhibits very heterogeneous cytokinetic char­
acteristics [158, 195, 196]. Conclusions based on cytokinetic informa-
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tion from experimental studies therefore need to be further evaluated in 
human cancer. 
Starvation for 24 hours in our tumour-bearing mice reduced their 
body weight by 20% and caused an inhibition of the tumour growth 
rate. There was a significant retardation of net tumour growth (I) in 
terms of tumour weight measurements, which was associated with a 
pronounced fall in tumour ODC activity (I). The retardation of tumour 
growth was associated with a reduced thymidine and BrdUrd incorpo­
ration into DNA, as well as a prolonged doubling time for those cells 
which were involved in cell cycle passage (I,II). However the con­
comitant finding of an unchanged DNA-synthesis time suggested that 
fewer cells were traversing the S+G2M phases. This suggestion was 
supported by the flow cytometric studies demonstrating reduced rela­
tive size of the S phase cytocompartment obviously due to accumula­
tion of tumour cells in the Gf)Gi phase (II). 
Although the ODC activity in the tumour tissue decreased in re­
sponse to starvation, the polyamine levels of tumour tissue were not 
reduced after starvation (I) This suggests a feedback mechanism by 
polyamines in the regulation of ODC activity [96]. The overall reduc­
tion in the number of cycling cells may reduce the demand for 
polyamines thus resulting in a down regulation of ODC activity. This 
implies that some other mechanism than tumour polyamine synthesis is 
involved in the prolongation of the potential doubling time after a 
period of starvation [27, 181]. 
The relative concentration of phophorus compounds in tumour tis­
sue was analysed with 3lP-NMR-spectroscopy and the HPLC-tech-
nique as reported in paper III. From the analysis of phosphorus 
metabolites, the energy charge of tumour tissue could be estimated 
[163, 178]. The energy charge represents an equilibrium of the adeny-
36 
late system (AMP,ADP and ATP) and is more than 0.85 in normal tis­
sues. In tumour tissue, this ratio was significantly reduced, which 
suggests a different equilibrium of energy production/utilisation in 
tumour tissues than seen in normal tissues [197]. After starvation, the 
energy charge of tumour tissue was significantly reduced in compari­
son with freely fed animals (III). This suggests that the proposed 
accumulation of cells in G(jGi was caused by lack of energy rather than 
a reduction of ODC activity. The reduced energy charge of the tumour 
tissue may lead to an increase of cells entering the quiescent phase 
(Go), thus reducing the growth fraction of the tumour [198] or alterna­
tively slowing the traverse through the Gi-phase. Furthermore, the 
apparent reduction of energy charge is a plausible explanation for the 
increased cell loss noted after starvation (II; [198]). These findings 
support the concept that experimental tumour growth is highly depen­
dent on substrate availability. 
Retardation of tumour growth was also obvious when the tumour-
bearing animals were treated with DFMO (1,11), which is a specific and 
irreversible inhibitor of ODC activity [77, 82, 129-133], Such an inac-
tivation of the enzyme was demonstrated in this study with a concomi­
tant increase in SAMD activity, which is a well-recognised compen­
satory regulation following effective ODC inhibition (Fig. 3; [77,199, 
200]). DFMO treatment seemed to have influenced the tumour, without 
any obvious deleterious effects on the host since the animals demon­
strated the same food and water intake as did untreated tumour-bearing 
control animals (I, [201]). 
The retardation of tumour growth in DFMO-treated mice was char­
acterised by a decreased labelling of DNA by BrdUrd and a prolonged 
DNA-synthesis time, concomitant with a prolonged potential doubling 
time. These findings, in combination with a relative accumulation of 
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cells in the S+G2M cytocompartment, suggest that DFMO treatment 
resulted in a decrease in tumour growth which primarily affected DNA 
synthesis and the proliferative phase prior to cell division [80, 132, 
202-206]. This finding is in contrast to some other reports, which indi­
cates that the role of polyamines may differ among different cell lines 
[207-210]. Furthermore, the results of our cytokinetic estimations sug­
gested that DFMO treatment increased the fractional loss of cells along 
cell cycle progression compared with tumours from both starved and 
freely fed animals (II). This may indicate that polyamine depletion 
results in a deteriorated regulation of DNA synthesis and cell growth. 
The energy charge of the tumour was not changed after DFMO 
treatment compared to freely fed animals. In fact, some of the high 
energy phosphates (PCr,ATP) were increased. This indicates that the 
decrease in DNA synthesis and the prolongation of the potential dou­
bling time caused by ODC inhibition was not mediated by alterations in 
cellular energy-generating or requiring processes (III). ODC is there­
fore suggested to have a direct role in the induction or promotion of cell 
division. 
Comparing the effects of polyamine depletion and starvation on 
tumour cytokinetics and energy state in tumour tissue, it is obvious that 
different mechanisms were operating in the retardation in tumour 
growth (I,II,III). Thus, polyamine depletion resulted in suppression of 
DNA synthesis and cell division with a preserved energy state, 
whereas starvation caused an accumulation of cells in GQGI due to 
energy shortage in tumours from starved animals. 
After starvation there was a reduction in tumour tissue of all the cy­
tokinetic variables described above (S phase, thymidine, BrdUrd) and 
ODC activity(II). Refeeding of the tumour-bearing animals after a 24-
hour period of starvation restored the energy charge in tumour tissue to 
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pre-starvation levels (III). There was a general response to refeeding 
with an activation of all variables but with different lag phases (II). 
Thus, ODC activity reached higher than pre-starvation values within 
one hour, while BrdUrd incorporation into DNA and the relative size 
of the S phase compartment were normalised after 4 and 8 hours 
respectively (II). The response of ODC activity to refeeding did not 
produce any changes in the polyamine levels in tumour tissue (I). The 
magnitude of the response of ODC activity was related to the com­
position of the food. Thus, oral intake of glucose demonstrated the 
strongest response in ODC activity compared to protein and lipid diets 
(I). However, intraperitoneal administration of glucose did not produce 
any response in ODC activity, although similar levels of glucose in 
serum were found to those after oral intake of glucose (I). There was 
also a difference in the response of plasma insulin to different sub­
strates and a significant correlation between ODC activity and plasma 
insulin was shown (r=0.82, p<0.01; II). Thus, ODC activity seemed 
to reflect acute changes of the tumour metabolism in response to 
refeeding and this response was at least partly mediated by insulin 
stimulation [100, 211-217]. These findings support the suggestion that 
ODC precede DNA synthesis and is activated to stimulate tumour 
growth [84, 104, 105, 108-111, 218-220], 
In this study, we have evaluated ODC activity as a marker for 
stimulation of tumour growth in cancer patients before and after artifi­
cial nutrition. The nutritional treatment was administered for 6-8 days 
either as total parenteral nutrition (V) or as formula diets supplied 
through a nasogastric tube (IV). These modes of nutrition are exten­
sively used as adjuvant treatment or for palliative purposes in cancer 
patients [2, 5, 14, 21-23, 27, 186, 187, 221, 222], We were not able 
to demonstrate any change in ODC activity after refeeding with artificial 
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nutrition (IV,V). There was no change in the size of the the growth 
fraction of the tumours after parenteral refeeding, evaluated by means 
of Ki-67 reactivity. However, an increase of the aneuploid compart­
ment size was observed in tumours after enteral nutrition compared to 
the control group (p<0.01; IV). This alteration was not found in 
patients receiving parenteral nutrition (V). The clinical significance of 
this finding remains to be determined. 
We conclude that tumour growth is highly dependent on food intake 
in our experimental tumour model and that there is little evidence in this 
study to support the fear that nutritional support will have any deleteri­
ous effects on tumour growth in cancer patients. 
During the past twenty years, the treatment of certain specific malig­
nant tumours has been successful in producing a better survival. 
Unfortunately, this is not the case for cancer disease in general and not 
for head and neck cancer, where survival statistics fail to improve in 
spite of advanced chemotherapeutic treatments in combination with 
traditional treatment [223, 224]. This fact is demonstrated in this study 
by the group of weight-loosing patients in paper IV, where only two of 
the 25 patients with an advanced tumour stage (T3-T4) have survived 
more than three years. These data emphasize the importance of identi­
fying such weight-loosing cancer patients and regarding nutritional 
support as an essential part of the oncological palliation treatment [15]. 
Sensitive cytokinetic methods are needed to assess tumour biology on a 
molecular level, in order to adjust the oncological treatment in each in­
dividual case. In this context, determination of ODC activity or 
polyamines in tumour tissue may reflect changes in growth characteris­
tics of cancer. 
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SUMMARY AND CONCLUSIONS 
This study provides evidence that nutritional modulation of the host af­
fects the growth rate of the MCG 101-sarcoma in mice. Starvation 
prolonged the potential doubling time of the tumour due to an accumu­
lation of cells in the G(jGi phase in the presence of limited energy avail­
ability. 
Refeeding restored tumour growth with an immediate activation of or­
nithine decarboxylase activity in tumour tissue. The increase in ODC 
activity preceded the increase in DNA synthesis and cell proliferation in 
response to refeeding. The activation of ODC was correlated to the car­
bohydrate content of the dietary intake and the levels of plasma insulin 
in the tumour-bearing animals. 
Specific inhibition of ODC with DFMO reduced tumour growth by in­
hibition of DNA synthesis, causing an accumulation of cells in the 
S+G2 phase and led to an increased fractional cell loss. However, the 
energy charge of such tumours was not affected by DFMO. This sug­
gests that ODC has a direct role in the induction and promotion of cell 
division. 
There was little evidence in this study to support the fear that nutritional 
support in cancer patients stimulates tumour cell proliferation. 
Determination of ODC activity in tumour tissue may have prognostic 
significance for survival and can probably be to used to monitor rapid 
changes in DNA-synthesis. 
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